ImmuPharma (LON:IMM) Trading Up 28.8% - Time to Buy?

Key Points

• ImmuPharma's stock price surged by 28.8% on Saturday, trading at GBX 13.98 ($0.19) after hitting a high of GBX 15.23 ($0.21).
• The company reported a negative earnings per share (EPS) of GBX (0.38) for the last quarter, with analysts expecting an EPS of approximately -339.0000022 for the current year.
• ImmuPharma focuses on developing peptide-based therapeutics for autoimmune diseases, with its lead program being Lupuzor™, targeting treatments for Lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price was up 28.8% during trading on Saturday . The company traded as high as GBX 15.23 ($0.21) and last traded at GBX 13.98 ($0.19). Approximately 44,749,293 shares were traded during mid-day trading, an increase of 451% from the average daily volume of 8,119,573 shares. The stock had previously closed at GBX 10.85 ($0.15).

ImmuPharma Stock Performance

The firm has a market capitalization of £69.86 million, a PE ratio of -1,570.67 and a beta of 1.53. The firm has a fifty day moving average of GBX 3.12 and a 200 day moving average of GBX 2.91.

ImmuPharma (LON:IMM - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Research analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.